Direct-to-Patient Drug Delivery in Clinical Trials: Enhancing Access and Convenience
Direct-to-Patient (DTP) drug delivery refers to the distribution of investigational medicinal products (IMPs) directly from clinical trial sites or central pharmacies to participant residences under controlled, regulatory-compliant conditions. This strategy reduces or eliminates the need for participants to travel to study sites for drug administration or pickup, supporting decentralized trial designs and participant-centric care models.
Click to read the full article.